UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION III
2443 WARRENVILLE ROAD, SUITE 210
LISLE, ILLINOIS 60532-4352

November 18, 2008

MEMORANDUM TO: Patricia J. Pelke, Chief
Materials Licensing Branch
Division of Nuclear Materials Safety

FROM: Christine A. Lipa, Chief
Materials Control, ISFSI, and Decommissioning Branch
Division of Nuclear Materials Safety

SUBJECT: RESPONSE TO TECHNICAL ASSISTANCE REQUEST #A-08 FOR SUBMITAL OF ANALYTICAL BIOCHEMISTRY LABORATORIES' REVISED BIOASSAY PROGRAM DATED OCTOBER 8, 2008

On October 21, 2008, you request our review of a letter dated October 10, 2008, including a revised bioassay program from Analytical Biochemistry Laboratories (ABC). Based on our review, we believe that the licensee has provided sufficient information to justify the dose conversion factors which are used to determine the internal doses from the urine bioassay results.

License No. 24-13365-01
Docket No. 030-05154

CONTACT: Peter J. Lee, DNMS
(630) 829-9870

Kevin Null

From: Peter Lee
Sent: Monday, November 24, 2008 4:43 PM
To: Kevin Null
Subject: Response to ABC's TAR

I did derive the urine bioassay dose conversion factors based on the biological half-lives, excretion fractions provided by the ABC. The results were consistent with the BCF stated in the Table 1 of OESH-813.